pinacidil has been researched along with Blood Pressure, High in 60 studies
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine dose-effect and concentration-effect relationships in hypertension for pinacidil and hydrochlorothiazide when given alone and together, we conducted a randomized, double-blind, 4 X 3 factorial, modified fixed-dose multicenter trial." | 9.06 | Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. ( Dornseif, BE; Goldberg, MR; Offen, WW; Rockhold, FW, 1989) |
| "Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator." | 9.06 | Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987) |
| "Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)." | 9.06 | Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987) |
| "Ten patients with mild to moderate hypertension were treated for 9 weeks with a tablet formulation of pinacidil." | 7.67 | Pinacidil monotherapy for hypertension. ( Ward, JW, 1984) |
| "Twenty patients with uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks (range 10-63 weeks)." | 7.67 | Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator. ( Breen, EG; Keogh, JA; Mulhall, D, 1985) |
| "A new vasodilator drug, pinacidil, N'-cyano-N-4-pyridyl-N'-1, 2,2-trimethylpropylguanidine, was studied in an open trial in 15 patients with moderate to severe hypertension." | 7.67 | Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension. ( Karatzas, NB; Koliopoulos, K; Papadoyannis, DE, 1984) |
| "Twenty three patients with essential hypertension who were uncontrolled on diuretic and/or beta-receptor antagonist therapy were treated additionally with the vasodilator, pinacidil, in an open study." | 7.67 | Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. ( D'Arcy, V; Hickey, MP; Laher, M; McCoy, D; Sullivan, P; Walsh, CH, 1985) |
| "In an open study increasing doses of a retarded tablet formulation of pinacidil were given twice daily for four weeks to 9 patients with untreated essential hypertension (WHO I-II)." | 7.66 | Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension. ( Carlsen, JE; Jensen, HA; Kardel, T; Tangø, M; Trap-Jensen, J, 1983) |
| "Pinacidil has been shown to inhibit Insulin release in vitro in isolated pancreatic beta cells." | 6.68 | No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension. ( Leenaers, AD; Ligtenberg, JJ; Reitsma, WD; Sluiter, WJ; Smit, AJ; Van Haeften, TW, 1996) |
| "We compared antihypertensive effects of monotherapy with pinacidil (N = 197) or prazosin (N = 204) in a randomized, parallel, double-blind dose-titration study in which hydrochlorothiazide or propranolol could be added for adverse events or lack of efficacy." | 6.66 | Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. ( Goldberg, MR; Rockhold, FW; Sushak, CS; Thompson, WL, 1988) |
| "Pinacidil is an orally administered antihypertensive drug that acts via direct relaxation of vascular smooth muscle to produce peripheral vasodilatation and a reduction in blood pressure without significant direct effects on cardiac electrophysiology." | 6.38 | Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. ( Brogden, RN; Friedel, HA, 1990) |
| "Pinacidil is a potassium channel opener that decreases blood pressure by reducing peripheral arterial resistance." | 5.28 | Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ( DeSante, KA; Goldberg, MR; Rockhold, FW; Thompson, WL, 1989) |
| "Pinacidil (N''-cyano-N-4-pyridyls-N'-1,2,2-trimethyl-propyl guanidine, monohydrate), a recently developed direct-acting vasodilator, was given intravenously in a dosage of 0." | 5.27 | Intravenous pinacidil in the acute treatment of hypertension. ( Rijk, MC; Thien, T, 1987) |
| "1 mg/kg) to patients with hypertension after 3 days of randomized, double-blind pretreatment with either propranolol or placebo." | 5.07 | Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment. ( Liang, CS; Stone, CK; Sullebarger, JT; Wellington, KL; Willick, A, 1991) |
| "Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)." | 5.06 | Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987) |
| "To determine dose-effect and concentration-effect relationships in hypertension for pinacidil and hydrochlorothiazide when given alone and together, we conducted a randomized, double-blind, 4 X 3 factorial, modified fixed-dose multicenter trial." | 5.06 | Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. ( Dornseif, BE; Goldberg, MR; Offen, WW; Rockhold, FW, 1989) |
| "Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator." | 5.06 | Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987) |
| "Forty-three patients with mild essential hypertension were randomized into two double-blind studies: pinacidil vs." | 5.06 | Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring. ( Collins, JB; Fisher, LD; Schirger, A; Sheps, SG; Shub, C; Spiekerman, RE; Zachariah, PK, 1986) |
| "The acute and chronic effects of pinacidil on blood pressure (BP) and renal function were investigated in 10 patients with moderate arterial hypertension insufficiently controlled by chronic beta-blockade." | 5.06 | Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy. ( Christensen, CK; Krusell, LR; Lederballe Pedersen, O, 1986) |
| " Up to now, the only use of PCAs has been in arterial hypertension, and the only drugs used are pinacidil, minoxidil and diazoxide." | 3.68 | [Potassium channel activators. Perspectives in the treatment of arterial hypertension]. ( Berdeaux, A; Giudicelli, JF; Richer, C, 1991) |
| "A new vasodilator drug, pinacidil, N'-cyano-N-4-pyridyl-N'-1, 2,2-trimethylpropylguanidine, was studied in an open trial in 15 patients with moderate to severe hypertension." | 3.67 | Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension. ( Karatzas, NB; Koliopoulos, K; Papadoyannis, DE, 1984) |
| "Twenty three patients with essential hypertension who were uncontrolled on diuretic and/or beta-receptor antagonist therapy were treated additionally with the vasodilator, pinacidil, in an open study." | 3.67 | Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. ( D'Arcy, V; Hickey, MP; Laher, M; McCoy, D; Sullivan, P; Walsh, CH, 1985) |
| "In an open study, thirteen chronic dialysis patients with nonvolume dependent uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks." | 3.67 | Long-term effects of pinacidil in hypertensive dialysis patients. ( Breen, EG; Keogh, JA; Mulhall, D, 1985) |
| "Twenty patients with uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks (range 10-63 weeks)." | 3.67 | Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator. ( Breen, EG; Keogh, JA; Mulhall, D, 1985) |
| "Ten patients with mild to moderate hypertension were treated for 9 weeks with a tablet formulation of pinacidil." | 3.67 | Pinacidil monotherapy for hypertension. ( Ward, JW, 1984) |
| "In an open study increasing doses of a retarded tablet formulation of pinacidil were given twice daily for four weeks to 9 patients with untreated essential hypertension (WHO I-II)." | 3.66 | Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension. ( Carlsen, JE; Jensen, HA; Kardel, T; Tangø, M; Trap-Jensen, J, 1983) |
| "Pinacidil has been shown to inhibit Insulin release in vitro in isolated pancreatic beta cells." | 2.68 | No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension. ( Leenaers, AD; Ligtenberg, JJ; Reitsma, WD; Sluiter, WJ; Smit, AJ; Van Haeften, TW, 1996) |
| "5mg bid, respectively, with significant attenuation of these effects at both hydrochlorothiazide dosage levels." | 2.66 | Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study. ( Goldberg, MR; Offen, WW, 1988) |
| "We compared antihypertensive effects of monotherapy with pinacidil (N = 197) or prazosin (N = 204) in a randomized, parallel, double-blind dose-titration study in which hydrochlorothiazide or propranolol could be added for adverse events or lack of efficacy." | 2.66 | Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. ( Goldberg, MR; Rockhold, FW; Sushak, CS; Thompson, WL, 1988) |
| "A satisfactory treatment of hypertension by these drugs may require the addition of diuretics and/or beta-blockers." | 2.38 | K(+)-channel openers: new antihypertensive drugs? ( Haeusler, G, 1990) |
| "Pinacidil is an orally administered antihypertensive drug that acts via direct relaxation of vascular smooth muscle to produce peripheral vasodilatation and a reduction in blood pressure without significant direct effects on cardiac electrophysiology." | 2.38 | Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. ( Brogden, RN; Friedel, HA, 1990) |
| "When pinacidil was given to patients unresponsive to hydrochlorothiazide (25 mg b." | 2.37 | Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. ( Goldberg, MR, 1988) |
| "Pinacidil is a potassium channel opener that decreases blood pressure by reducing peripheral arterial resistance." | 1.28 | Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ( DeSante, KA; Goldberg, MR; Rockhold, FW; Thompson, WL, 1989) |
| "After dosage titration from the age of 1 month to the age of 3 months, spontaneously hypertensive rats (SHR) were treated with pinacidil 10 mg/kg daily until the age of 6 or 12 months." | 1.27 | Aggressive long-term antihypertensive therapy with pinacidil does not cause regression of cardiovascular hypertrophy in the spontaneously hypertensive rat. ( Baandrup, U; Jespersen, LT; Lederballe, O; Mikkelsen, EO; Nyborg, NC, 1986) |
| "Pinacidil (N''-cyano-N-4-pyridyls-N'-1,2,2-trimethyl-propyl guanidine, monohydrate), a recently developed direct-acting vasodilator, was given intravenously in a dosage of 0." | 1.27 | Intravenous pinacidil in the acute treatment of hypertension. ( Rijk, MC; Thien, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (65.00) | 18.7374 |
| 1990's | 16 (26.67) | 18.2507 |
| 2000's | 3 (5.00) | 29.6817 |
| 2010's | 1 (1.67) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Petersen, HJ | 2 |
| Nielsen, CK | 2 |
| Arrigoni-Martelli, E | 2 |
| Takemoto, T | 2 |
| Eda, M | 2 |
| Okada, T | 2 |
| Sakashita, H | 2 |
| Matzno, S | 2 |
| Gohda, M | 2 |
| Ebisu, H | 1 |
| Nakamura, N | 2 |
| Fukaya, C | 2 |
| Hihara, M | 1 |
| Li, Y | 2 |
| Aziz, Q | 2 |
| Anderson, N | 1 |
| Ojake, L | 1 |
| Tinker, A | 2 |
| Thomas, AM | 1 |
| Gomes, J | 1 |
| Ang, R | 1 |
| Sones, WR | 1 |
| Ng, KE | 1 |
| Gee, L | 1 |
| Fields, AM | 1 |
| Richards, TA | 1 |
| Felton, JA | 1 |
| Felton, SK | 1 |
| Bayer, EZ | 1 |
| Ibrahim, IN | 1 |
| Kaye, AD | 1 |
| Aqil, M | 1 |
| Ali, A | 1 |
| Sultana, Y | 1 |
| Dubey, K | 1 |
| Najmi, AK | 1 |
| Pillai, KK | 1 |
| Blanco-Rivero, J | 1 |
| Gamallo, C | 1 |
| Aras-López, R | 1 |
| Cobeño, L | 1 |
| Cogolludo, A | 1 |
| Pérez-Vizcaino, F | 1 |
| Ferrer, M | 1 |
| Balfagon, G | 1 |
| Ward, JW | 1 |
| Koliopoulos, K | 1 |
| Papadoyannis, DE | 1 |
| Karatzas, NB | 1 |
| Ramsay, LE | 1 |
| Freestone, S | 1 |
| Carlsen, JE | 5 |
| Kardel, T | 3 |
| Jensen, HA | 2 |
| Tangø, M | 2 |
| Trap-Jensen, J | 4 |
| Hilden, T | 1 |
| Olsen, UB | 1 |
| Clapham, JC | 1 |
| Trail, BK | 1 |
| Hamilton, TC | 1 |
| Krusell, LR | 2 |
| Jespersen, LT | 2 |
| Thomsen, K | 1 |
| Pedersen, OL | 1 |
| Numaguchi, K | 1 |
| Egashira, K | 1 |
| Sakata, M | 1 |
| Shimokawa, H | 1 |
| Takeshita, A | 1 |
| Ligtenberg, JJ | 1 |
| Leenaers, AD | 1 |
| Van Haeften, TW | 1 |
| Smit, AJ | 1 |
| Sluiter, WJ | 1 |
| Reitsma, WD | 1 |
| Nishimura, M | 1 |
| Takahashi, H | 1 |
| Nanbu, A | 1 |
| Sakamoto, M | 1 |
| Nakanishi, T | 1 |
| Yoshimura, M | 1 |
| Hayashi, K | 1 |
| Kwan, YW | 1 |
| To, KW | 1 |
| Lau, WM | 1 |
| Tsang, SH | 1 |
| Wang, H | 1 |
| Fletcher, AE | 1 |
| Battersby, C | 1 |
| Adnitt, P | 1 |
| Underwood, N | 1 |
| Jurgensen, HJ | 2 |
| Bulpitt, CJ | 1 |
| Lawson, K | 1 |
| Barras, M | 1 |
| Zazzi-Sudriez, E | 1 |
| Martin, DJ | 1 |
| Armstrong, JM | 1 |
| Hicks, PE | 1 |
| Corder, CN | 1 |
| Goldberg, MR | 7 |
| Alaupovic, PA | 1 |
| Price, MD | 1 |
| Furste, SS | 1 |
| Giudicelli, JF | 1 |
| Richer, C | 1 |
| Berdeaux, A | 1 |
| Stone, CK | 1 |
| Wellington, KL | 1 |
| Willick, A | 1 |
| Sullebarger, JT | 1 |
| Liang, CS | 2 |
| Haeusler, G | 1 |
| Friedel, HA | 1 |
| Brogden, RN | 1 |
| Smallwood, JK | 1 |
| Steinberg, MI | 1 |
| Ahnfelt-Rønne, I | 1 |
| Yuhara, M | 1 |
| Rudd, P | 1 |
| Byyny, RL | 1 |
| Zachary, V | 1 |
| LoVerde, ME | 1 |
| Titus, C | 1 |
| Mitchell, WD | 1 |
| Marshall, G | 1 |
| Rockhold, FW | 3 |
| Thompson, WL | 2 |
| DeSante, KA | 1 |
| Offen, WW | 2 |
| Dornseif, BE | 1 |
| Lund, JO | 2 |
| McNair, A | 1 |
| Eggertsen, R | 1 |
| Hansson, L | 1 |
| Christensen, CK | 1 |
| Lederballe Pedersen, O | 1 |
| Izzo, JL | 1 |
| Licht, MR | 1 |
| Smith, RJ | 1 |
| Larrabee, PS | 1 |
| Radke, KJ | 1 |
| Kallay, MC | 1 |
| Baandrup, U | 1 |
| Nyborg, NC | 1 |
| Mikkelsen, EO | 1 |
| Lederballe, O | 1 |
| Rehling, M | 1 |
| Sterndorff, B | 2 |
| Johansen, P | 2 |
| Callaghan, JT | 1 |
| Brunelle, R | 1 |
| Steensgaard-Hansen, F | 1 |
| Sushak, CS | 1 |
| Rijk, MC | 1 |
| Thien, T | 1 |
| Abraham, PA | 1 |
| Halstenson, CE | 1 |
| Matzke, GR | 1 |
| Keane, WF | 1 |
| Solomon, RJ | 1 |
| Weinberg, MS | 1 |
| Cinquegrani, MP | 1 |
| Zachariah, PK | 1 |
| Sheps, SG | 1 |
| Schirger, A | 1 |
| Fisher, LD | 1 |
| Shub, C | 1 |
| Collins, JB | 1 |
| Spiekerman, RE | 1 |
| Muiesan, G | 1 |
| Fariello, R | 1 |
| Muiesan, ML | 1 |
| Christensen, OE | 1 |
| D'Arcy, V | 1 |
| Laher, M | 1 |
| McCoy, D | 1 |
| Sullivan, P | 1 |
| Walsh, CH | 1 |
| Hickey, MP | 1 |
| Breen, EG | 2 |
| Mulhall, D | 2 |
| Keogh, JA | 2 |
| Caruana, MP | 1 |
| Al-Khawaja, I | 1 |
| Royston, P | 1 |
| Raftery, EB | 1 |
| Matsuda, S | 1 |
| Ueda, M | 1 |
5 reviews available for pinacidil and Blood Pressure, High
| Article | Year |
|---|---|
Cardiovascular ATP-sensitive K+ channel as a new molecular target for development of antihypertensive drugs.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Humans; Hypertension; Pinacidil; Potassium | 1998 |
K(+)-channel openers: new antihypertensive drugs?
Topics: Antihypertensive Agents; Benzopyrans; Cromakalim; Dihydropyridines; Guanidines; Hemodynamics; Humans | 1990 |
Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
Topics: Animals; Antihypertensive Agents; Drug Interactions; Guanidines; Humans; Hypertension; Pinacidil | 1990 |
Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
Topics: Antihypertensive Agents; Guanidines; Humans; Hypertension; Pinacidil; Potassium Channels | 1988 |
Vasodilators in hypertension--a review with special emphasis on the combined use of vasodilators and beta-adrenoceptor blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1985 |
23 trials available for pinacidil and Blood Pressure, High
| Article | Year |
|---|---|
Preliminary evaluation of pinacidil in hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Drug Evaluation; Female; Guanidines; Humans; Hypertension; | 1983 |
No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension.
Topics: Adult; Double-Blind Method; Female; Guanidines; Humans; Hypertension; Insulin; Insulin Secretion; Ma | 1996 |
Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Data Interpre | 1992 |
Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Apolipoproteins; Double-Blind Method; Drug Therapy, Combination; Gua | 1992 |
Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Female; Forearm; Guanidines; Heart Rate; Hemody | 1991 |
The natural history of medication compliance in a drug trial: limitations of pill counts.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Female; Guanidines; Humans; Hydralazine; Hyperten | 1989 |
Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Female; Guanidines | 1989 |
Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiac Output; Double-Blind Method; Drug Evalua | 1985 |
Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; beta 2-Microglobulin; Blood Pressure; Clinical Tria | 1986 |
Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 1987 |
Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Glomerular Filtration Rate; Guani | 1988 |
Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Femal | 1988 |
Comparative effects of pinacidil and nifedipine in the treatment of arterial hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Guanidines; | 1988 |
Double-blind comparator trials with pinacidil, a potassium channel opener.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Guanidines; | 1988 |
Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 1988 |
The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice.
Topics: Antihypertensive Agents; Blood Pressure; Electrocardiography; Family Practice; Female; Guanidines; H | 1988 |
Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Echocardiography; Female; Guanidines; Heart Ventricle | 1988 |
Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Data Interpretation, Statistical; Double-Blin | 1988 |
Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-B | 1987 |
Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as To | 1987 |
Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Forearm; Guanidin | 1988 |
Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.
Topics: Adult; Antihypertensive Agents; Circadian Rhythm; Double-Blind Method; Female; Guanidines; Heart Rat | 1986 |
Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Body Weight; Catecholamines; Chloro | 1985 |
32 other studies available for pinacidil and Blood Pressure, High
| Article | Year |
|---|---|
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
Topics: Animals; Antihypertensive Agents; Dogs; Female; Guanidines; Hypertension; Lethal Dose 50; Mice; Rats | 1978 |
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
Topics: 4-Aminopyridine; Amifampridine; Animals; Antihypertensive Agents; Biomechanical Phenomena; Glyburide | 1994 |
Endothelial ATP-Sensitive Potassium Channel Protects Against the Development of Hypertension and Atherosclerosis.
Topics: Animals; Antihypertensive Agents; Apolipoproteins E; Atherosclerosis; Blood Pressure; Diet, High-Fat | 2020 |
The ATP-sensitive potassium channel subunit, Kir6.1, in vascular smooth muscle plays a major role in blood pressure control.
Topics: Animals; Blood Pressure; Calcitonin Gene-Related Peptide; Disease Models, Animal; Hypertension; In V | 2014 |
Analysis of responses to valerian root extract in the feline pulmonary vascular bed.
Topics: Acetylcholine; Animals; Arachidonic Acid; Bradykinin; Calcium Channel Agonists; Cats; Disease Models | 2003 |
In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: a technical note.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Blood Pressure; Chemistry, Pharmaceutic | 2006 |
Decreased expression of aortic KIR6.1 and SUR2B in hypertension does not correlate with changes in the functional role of K(ATP) channels.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; ATP-Binding Cassette Transporters; Blotting, West | 2008 |
Pinacidil monotherapy for hypertension.
Topics: Adult; Antihypertensive Agents; Body Weight; Female; Guanidines; Humans; Hypertension; Male; Middle | 1984 |
Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Female; Guanidines; Humans; Hypertension; Male; Middle Aged; P | 1984 |
Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Drug Evaluation; Female; Guanidines; Heart | 1983 |
Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.
Topics: Adult; Blood Pressure; Cardiac Output; Female; Guanidines; Heart Rate; Hemodynamics; Humans; Hydrala | 1981 |
N''-cyano-N-4-pyridyl-N'-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): a new, potent vasodilator.
Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Dose-Response Relationship, Drug; Guanidines; Heart R | 1980 |
K+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive rat.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Benzopyrans; Blood Glucose; Blood Pressure; | 1994 |
Proximal renal tubular pressure-natriuresis-relation in essential hypertensives following acute vasodilatation.
Topics: Adult; Analysis of Variance; Blood Pressure; Female; Guanidines; Humans; Hypertension; Kidney Tubule | 1993 |
Coronary vascular ATP-sensitive potassium channels are activated to a greater extent in spontaneously hypertensive rats than in Wistar-Kyoto rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Triphosphate; Animals; | 1996 |
Cerebral adenosine triphosphate-sensitive K+ channels may be impaired during acute cerebral ischemia in spontaneously hypertensive rats.
Topics: Adenosine Triphosphate; Adrenergic alpha-Antagonists; Animals; Antidiuretic Hormone Receptor Antagon | 1996 |
Synthesis and pharmacological evaluation of N-(6-functionalized-amino-3-pyridyl)-N'-bicycloalkyl-N''-cyanoguanidine s as antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Depression, Chemical; Diuretics; Guanidines; Hyper | 1996 |
Comparison of the vascular relaxant effects of ATP-dependent K+ channel openers on aorta and pulmonary artery isolated from spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Adenosine Triphosphate; Aminoquinolines; Animals; Aorta, Thoracic; Apamin; Benzopyrans; Charybdotoxi | 1999 |
Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
Topics: Animals; Aorta; Benzopyrans; Cromakalim; Cyclopentanes; Dihydropyridines; Dose-Response Relationship | 1992 |
[Potassium channel activators. Perspectives in the treatment of arterial hypertension].
Topics: Antihypertensive Agents; Benzopyrans; Cromakalim; Guanidines; Humans; Hypertension; Niacinamide; Nic | 1991 |
Cardiac electrophysiological effects of pinacidil and related pyridylcyanoguanidines: relationship to antihypertensive activity.
Topics: Action Potentials; Animals; Antihypertensive Agents; Guanidines; Heart; Hemodynamics; Hypertension; | 1988 |
Pinacidil: history, basic pharmacology, and therapeutic implications.
Topics: Animals; Guanidines; History, 20th Century; Humans; Hypertension; Pinacidil; Vasodilator Agents | 1988 |
[Clinical application of vascular smooth muscle relaxants in the treatment of hypertension].
Topics: Guanidines; Humans; Hydralazine; Hypertension; Nitroglycerin; Parasympatholytics; Pinacidil; Pyridaz | 1989 |
Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
Topics: Adult; Age Factors; Antihypertensive Agents; Biological Availability; Creatinine; Female; Guanidines | 1989 |
Aggressive long-term antihypertensive therapy with pinacidil does not cause regression of cardiovascular hypertrophy in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Guanidines; Hypertension; Male; Pina | 1986 |
Pinacidil: potassium channel openers in the treatment of hypertension. Proceedings of a symposium. Copenhagen, 10-11 March, 1988.
Topics: Animals; Antihypertensive Agents; Guanidines; Humans; Hypertension; Pinacidil | 1988 |
Intravenous pinacidil in the acute treatment of hypertension.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Epinephrine; Female; Guanidines; Heart R | 1987 |
Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Guanidines; Humans; Hypertension; Male; Middle Aged; Pinacidil; | 1985 |
Long-term effects of pinacidil in hypertensive dialysis patients.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Electrocardiography; Female; Guanidines; | 1985 |
Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Female; Guanidines; Heart Rate; Humans; Hypert | 1985 |
The effects of long-acting pinacidil on intra-arterial blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Female; Guanidines; Humans; Hy | 1985 |
[Pharmacological studies on pinacidil, a new anti-hypertensive agent. 1. Antihypertensive effects in SHR and DOC/saline hypertensive rats].
Topics: Administration, Oral; Animals; Antihypertensive Agents; Desoxycorticosterone; Female; Guanidines; Hy | 1985 |